FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005124541> ?p ?o ?g. }

• W2005124541 endingPage "563" @default.
• W2005124541 startingPage "555" @default.
• W2005124541 abstract "Effect of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency.BackgroundWhereas angiotensin converting enzyme inhibitors and angiotensin type 1 receptor antagonists have beneficial effects in the remnant model of renal failure, calcium channel blockers do not consistently improve renal disease in this model. This study examined whether these different means of blood pressure reduction have different effects on renal levels of angiotensin (Ang) and bradykinin peptides.MethodsRats subjected to five-sixths nephrectomy were divided into groups with similar hypertension and proteinuria at 4 to 5 Weeks. They then received either no treatment, or enalapril, losartan or nifedipine for 2 Weeks. Following repeat measurements of proteinuria and blood pressure, Ang II and bradykinin peptides were measured in the remnant kidney and renin, Ang II, and aldosterone were measured in the plasma.ResultsAll three drugs had equivalent blood pressure-lowering effects. Enalapril and losartan reduced proteinuria but nifedipine did not. Reduction of proteinuria in rats treated with enalapril and losartan was associated with a reduction in Ang II levels in both the peri-infarct and intact portions of the remnant kidney. By contrast, nifedipine increased Ang II levels in the intact portion of the remnant kidney. Losartan reduced bradykinin levels in the peri-infarct portion of the remnant kidney while enalapril reduced bradykinin levels in the intact portion of the remnant kidney. Nifedipine had no effect on intrarenal bradykinin levels.ConclusionsThe differential effects of enalapril, losartan and nifedipine on proteinuria and intrarenal Ang II and bradykinin levels suggest that the ability of an antihypertensive to decrease proteinuria may depend on its ability to decrease kidney Ang II and bradykinin levels. Effect of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency. Whereas angiotensin converting enzyme inhibitors and angiotensin type 1 receptor antagonists have beneficial effects in the remnant model of renal failure, calcium channel blockers do not consistently improve renal disease in this model. This study examined whether these different means of blood pressure reduction have different effects on renal levels of angiotensin (Ang) and bradykinin peptides. Rats subjected to five-sixths nephrectomy were divided into groups with similar hypertension and proteinuria at 4 to 5 Weeks. They then received either no treatment, or enalapril, losartan or nifedipine for 2 Weeks. Following repeat measurements of proteinuria and blood pressure, Ang II and bradykinin peptides were measured in the remnant kidney and renin, Ang II, and aldosterone were measured in the plasma. All three drugs had equivalent blood pressure-lowering effects. Enalapril and losartan reduced proteinuria but nifedipine did not. Reduction of proteinuria in rats treated with enalapril and losartan was associated with a reduction in Ang II levels in both the peri-infarct and intact portions of the remnant kidney. By contrast, nifedipine increased Ang II levels in the intact portion of the remnant kidney. Losartan reduced bradykinin levels in the peri-infarct portion of the remnant kidney while enalapril reduced bradykinin levels in the intact portion of the remnant kidney. Nifedipine had no effect on intrarenal bradykinin levels. The differential effects of enalapril, losartan and nifedipine on proteinuria and intrarenal Ang II and bradykinin levels suggest that the ability of an antihypertensive to decrease proteinuria may depend on its ability to decrease kidney Ang II and bradykinin levels." @default.
• W2005124541 created "2016-06-24" @default.
• W2005124541 creator A5022682140 @default.
• W2005124541 creator A5022690671 @default.
• W2005124541 creator A5065227292 @default.
• W2005124541 date "2002-02-01" @default.
• W2005124541 modified "2023-10-17" @default.
• W2005124541 title "Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency" @default.
• W2005124541 cites W1644254267 @default.
• W2005124541 cites W1975291885 @default.
• W2005124541 cites W1982525745 @default.
• W2005124541 cites W1991364659 @default.
• W2005124541 cites W1998509977 @default.
• W2005124541 cites W2009890346 @default.
• W2005124541 cites W2017410383 @default.
• W2005124541 cites W2018154498 @default.
• W2005124541 cites W2028626467 @default.
• W2005124541 cites W2031534703 @default.
• W2005124541 cites W2031959683 @default.
• W2005124541 cites W2033011961 @default.
• W2005124541 cites W2049703417 @default.
• W2005124541 cites W2053171397 @default.
• W2005124541 cites W2063445233 @default.
• W2005124541 cites W2069095197 @default.
• W2005124541 cites W2071509026 @default.
• W2005124541 cites W2092596981 @default.
• W2005124541 cites W2095253772 @default.
• W2005124541 cites W2104598696 @default.
• W2005124541 cites W2105885500 @default.
• W2005124541 cites W2115236802 @default.
• W2005124541 cites W2118547023 @default.
• W2005124541 cites W2129537648 @default.
• W2005124541 cites W2131873159 @default.
• W2005124541 cites W2132128862 @default.
• W2005124541 cites W2134032718 @default.
• W2005124541 cites W2135285685 @default.
• W2005124541 cites W2141128221 @default.
• W2005124541 cites W2144403565 @default.
• W2005124541 cites W2149496619 @default.
• W2005124541 cites W2157734027 @default.
• W2005124541 cites W2163158476 @default.
• W2005124541 cites W2186699196 @default.
• W2005124541 cites W2243393341 @default.
• W2005124541 cites W2321986725 @default.
• W2005124541 doi "https://doi.org/10.1046/j.1523-1755.2002.00141.x" @default.
• W2005124541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11849396" @default.
• W2005124541 hasPublicationYear "2002" @default.
• W2005124541 type Work @default.
• W2005124541 sameAs 2005124541 @default.
• W2005124541 citedByCount "17" @default.
• W2005124541 countsByYear W20051245412013 @default.
• W2005124541 countsByYear W20051245412014 @default.
• W2005124541 countsByYear W20051245412017 @default.
• W2005124541 countsByYear W20051245412020 @default.
• W2005124541 crossrefType "journal-article" @default.
• W2005124541 hasAuthorship W2005124541A5022682140 @default.
• W2005124541 hasAuthorship W2005124541A5022690671 @default.
• W2005124541 hasAuthorship W2005124541A5065227292 @default.
• W2005124541 hasBestOaLocation W20051245411 @default.
• W2005124541 hasConcept C126322002 @default.
• W2005124541 hasConcept C126894567 @default.
• W2005124541 hasConcept C134018914 @default.
• W2005124541 hasConcept C170493617 @default.
• W2005124541 hasConcept C27016395 @default.
• W2005124541 hasConcept C2775940317 @default.
• W2005124541 hasConcept C2779066535 @default.
• W2005124541 hasConcept C2779561371 @default.
• W2005124541 hasConcept C2779591629 @default.
• W2005124541 hasConcept C2779611605 @default.
• W2005124541 hasConcept C2780091579 @default.
• W2005124541 hasConcept C2780288358 @default.
• W2005124541 hasConcept C2908929049 @default.
• W2005124541 hasConcept C519063684 @default.
• W2005124541 hasConcept C71924100 @default.
• W2005124541 hasConcept C84393581 @default.
• W2005124541 hasConceptScore W2005124541C126322002 @default.
• W2005124541 hasConceptScore W2005124541C126894567 @default.
• W2005124541 hasConceptScore W2005124541C134018914 @default.
• W2005124541 hasConceptScore W2005124541C170493617 @default.
• W2005124541 hasConceptScore W2005124541C27016395 @default.
• W2005124541 hasConceptScore W2005124541C2775940317 @default.
• W2005124541 hasConceptScore W2005124541C2779066535 @default.
• W2005124541 hasConceptScore W2005124541C2779561371 @default.
• W2005124541 hasConceptScore W2005124541C2779591629 @default.
• W2005124541 hasConceptScore W2005124541C2779611605 @default.
• W2005124541 hasConceptScore W2005124541C2780091579 @default.
• W2005124541 hasConceptScore W2005124541C2780288358 @default.
• W2005124541 hasConceptScore W2005124541C2908929049 @default.
• W2005124541 hasConceptScore W2005124541C519063684 @default.
• W2005124541 hasConceptScore W2005124541C71924100 @default.
• W2005124541 hasConceptScore W2005124541C84393581 @default.
• W2005124541 hasIssue "2" @default.
• W2005124541 hasLocation W20051245411 @default.
• W2005124541 hasLocation W20051245412 @default.
• W2005124541 hasOpenAccess W2005124541 @default.
• W2005124541 hasPrimaryLocation W20051245411 @default.
• W2005124541 hasRelatedWork W2031513528 @default.
• W2005124541 hasRelatedWork W2037598090 @default.

• next